Alpna Seth - May 1, 2023 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
May 1, 2023
Transactions value $
$0
Form type
4
Date filed
5/3/2023, 04:45 PM
Previous filing
Oct 31, 2022
Next filing
Jun 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Stock Option (right to buy) Award $0 +20K $0.00 20K May 1, 2023 Common Stock 20K $46.07 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-twelfth (1/12th) of the shares subject to the option shall vest in equal quarterly installments commencing on August 1, 2023, subject to the Reporting Person continuing to provide service through each such date.